Lung Cancer Clinical Trial
Met Non Small Cell Cancer Registry (MOMENT)
Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.
Full Description
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
Eligibility Criteria
Inclusion Criteria:
Participants who signed ICF
Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
Participants who are starting or are already being treated with systemic therapy
Exclusion Criteria:
Participants who are enrolled in a clinical trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Fort Lauderdale Florida, 33308, United States
Nashville Tennessee, 37212, United States
Klagenfurt am Wörthersee , , Austria
Wien , , Austria
Roeselare , , Belgium
Sint-Niklaas , , Belgium
Yvoir , , Belgium
Ottawa , , Canada
Toronto , , Canada
Toronto , , Canada
Tampere , , Finland
Turku , , Finland
Cholet , , France
Lille , , France
Paris , , France
Toulouse , , France
Grosshansdorf , , Germany
Heidelberg , , Germany
Ashdod , , Israel
Ashdod , , Israel
Haifa , , Israel
Haifa , , Israel
Haifa , , Israel
Haifa , , Israel
Haifa , , Israel
Haifa , , Israel
Jerusalem , , Israel
Jerusalem , , Israel
Ramat Gan , , Israel
Ramat Gan , , Israel
Tel Aviv-Yafo , , Israel
Tel Aviv , , Israel
Milano , , Italy
Milano , , Italy
Orbassano (TO) , , Italy
Orbassano , , Italy
Roma , , Italy
Amsterdam , , Netherlands
Groningen , , Netherlands
Leiden , , Netherlands
Lisboa , , Portugal
Lisboa , , Portugal
Porto Covo , , Portugal
Porto , , Portugal
las Palmas de Gran Canaria , , Spain
Malaga , , Spain
Sevilla , , Spain
Valencia , , Spain
Linköping , , Sweden
Birmingham , , United Kingdom
Birmingham , , United Kingdom
Guildford , , United Kingdom
London , , United Kingdom
Sutton Coldfield , , United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.